Origin Sciences at Key Medical Conferences

It’s been an especially busy few months for our Chief Scientific Officer, Dr. Daniel Wise and Chief Technology Officer, Prof. Andrew Page who have both been in demand with speaking invitations from several leading conferences and forums.

Conferences are where ideas converge. They provide a platform to not only share findings but also to exchange perspectives, challenge assumptions and spark collaborations, highlighting the importance of the work we do and the broader impact it can have.

The NIHR’s flagship Bioaccelerator Conference, held at London's Imperial College, saw Origin CSO, Dr, Daniel Wise appear alongside a number of keynote speakers addressing the latest advancements in biomarker research. Expanding for the audience upon our work in biomarker development and sharing real-world successes, the talk examined overcoming obstacles in translating research into deliverable clinical solutions and invited numerous questions and spin-out conversations.

At the GENEWIZ UK Omics Discovery Day in Oxford, an event dedicated to the latest advancements in genomics, transcriptomics, and proteomics, CSO Dr. Daniel Wise was invited to share some of our recent advances in colorectal cancer detection and showcased how we are using the power of individual and integrated omic technologies to make tangible, real world impact.

Chief Technology Officer, Prof. Andrew Page, was asked to present at the Applied Bioinformatics and Public Health Microbiology conference at the Wellcome Genome Campus in Cambridge. A leader in the field, Pref. Page drew on illustrative real-world examples of collaboration to give context to the emergence of Microbial Bioinformatics as part of a wide ranging exploration of exciting topics surrounding approaches to data-driven genomics in public health settings.

One of Europe's largest events in the field of Cancer Research, the Annual Congress of the European Association for Cancer Research (EACR), saw Origin CSO, Dr. Daniel Wise, invited to speak during the "Illumina Inc.: Empowering discoveries across omics" session. Addressing a filled auditorium, Dr. Wise presented details of our current work using a novel mucus biospecimen and integrated omics to enable the early detection of colorectal cancer (CRC) which generated considerable interest and further post-presentation discussion.

We now have a break until our next conference participation at the European Society of Coloproctology’s 20th Annual Conference - Tripartite Colorectal – in September.